Imugene Limited

📍 Sydney, Australia🗓 Founded 2013👥 65 employees💰 Last funded Aug 2019
Biotechnology Research🌐 imugene.com
Website LinkedIn
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Australia
1
Frequently asked questions
Who invested in Imugene Limited?
Imugene Limited has 2 investors on record on gritt.io and 2 late-stage investors.
When did Imugene Limited last raise funding?
The most recent investment in Imugene Limited recorded on gritt.io was in August 2019.
When was Imugene Limited founded?
Imugene Limited was founded in 2013.
What industry is Imugene Limited in?
Imugene Limited operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Imugene Limited based?
Imugene Limited is headquartered in Sydney, Australia.